Abstract |
The new triazole, D0870, was tested for therapeutic efficacy in the treatment of experimental systemic murine coccidioidomycosis. D0870 at 1 or 10 mg kg-1 daily, or 10 or 100 mg kg-1 every other day, and fluconazole at 100 mg kg-1 daily prolonged survival (P < 0.01), but were equivalent to each other. D0870 at 10 mg kg-1 daily or 100 mg kg-1 every other day cured 20 or 30% of mice of residual infection, respectively, and were superior to 100 mg kg-1 of fluconazole daily (P < 0.001). D0870 is approximately 10-fold more active than fluconazole. It is a promising treatment for coccidioidomycosis, which warrants further testing.
|
Authors | K V Clemons, D A Stevens |
Journal | Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology
(J Med Vet Mycol)
Vol. 32
Issue 4
Pg. 323-6
( 1994)
ISSN: 0268-1218 [Print] England |
PMID | 7983578
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antifungal Agents
- Triazoles
- ICI 195739
- Fluconazole
|
Topics |
- Animals
- Antifungal Agents
(therapeutic use)
- Coccidioides
(isolation & purification)
- Coccidioidomycosis
(drug therapy)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Fluconazole
(therapeutic use)
- Liver
(microbiology)
- Lung
(microbiology)
- Mice
- Mice, Inbred Strains
- Spleen
(microbiology)
- Stereoisomerism
- Triazoles
(therapeutic use)
|